Claritev Corporation

NYSE:CTEV

Medical - Healthcare Information Services

Healthcare
$22.30 +1.41%

+$0.42 today

Market cap
$380.77M
Beta
0.77
P/E (TTM)
-1.8
EPS (TTM)
-$17.16
52W Low $11.50High $74.07

Volume 0.31M

Average 0.14M

CTEV Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Claritev CorporationNYSE: CTEV

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $180.17M rose 198.1% year over year, ahead of the +58.9% change in trailing-twelve-month cost of revenue. Sequentially, it rose 130.9% from the prior quarter. Over 3 fiscal years it compounded at +50.7% a year.

Context

  • Cost of revenue amounted to 72.4% of revenue in FY2025, up 46.7 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +198.1% holds above the trailing-twelve-month pace of +58.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$180.17M+130.9% QoQ
Last fiscal yearDec 2025
$698.84M+191.9% YoY
LTMMar 2026
$381.09M+58.9% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+198.1%——
1 year+191.9%——
3-year CAGR+50.7%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
698.84M USD
Year-over-year change
+191.9%
4-year CAGR
+41.3%

Cost of Revenue vs competitors

How CTEV compares with its peers on the latest reported figures

  • CTEV's LTM Mar 2026 cost of revenue of $381.09M is the 4th highest of the 11 companies compared; the peer median is $75.98M.
  • Its year-over-year change of +58.9% is the 2nd highest of 9, against a peer median of +8.0%.
  • Cost of revenue amounts to 38.9% of revenue for CTEV, versus a peer median of 23.2%.
CTEV Competitors Peer median
Cost of Revenue for CTEV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EVHEvolent Health, Inc.LTM Mar 2026$1.62B -20.2%+15.4%85.9%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$769.47M +2.0%+10.4%46.8%
OPKOPKO Health, Inc.LTM Mar 2026$449.04M -8.4%-12.5%77.3%
CTEVClaritev CorporationLTM Mar 2026$381.09M +58.9%+50.7%38.9%
GDRXGoodRx Holdings, Inc.LTM Mar 2026$105.91M +115.7%-4.0%13.4%
INMDInMode Ltd.LTM Mar 2026$83.03M +6.0%+2.7%22.2%
AXGNAxoGen, Inc.LTM Sep 2026$68.92M +27.2%+24.8%25.8%
LFMDLifeMD, Inc.LTM Mar 2026$30.96M +10.1%+28.2%14.1%
IRMDIRadimed CorporationLTM Mar 2026$19.99M +15.2%+17.5%23.2%
SANASana Biotechnology, Inc.LTM Mar 2026$2.39M ———
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$76K ——4.0%
Peer median (excluding CTEV) $75.98M+8.0%+12.9%23.2%

Competitors are the stored peer set for CTEV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.12B1.08B961.52M930.62M965.41M
Cost of Revenue175.29M204.1M235.47M239.4M698.84M
Gross Profit942.31M875.62M726.06M691.22M266.58M
Gross Margin84.3%81.1%75.5%74.3%27.6%
Research & Development00000
Selling, General & Admin151.1M132.14M135.99M160.22M221.52M
Operating Expenses556.19M1.24B564.07M2.08B221.52M
Depreciation & Amortization412.06M415.66M425.79M436.44M448.45M
EBITDA814.99M158.32M651.93M(1.01B)475.44M
EBITDA Margin72.9%14.7%67.8%-108.3%49.2%
Operating Income386.12M(362.73M)161.98M(1.39B)45.06M
Operating Margin34.5%-33.6%16.8%-149.4%4.7%
Interest Income30K3.5M8.23M3.13M1.56M
Interest Expense267.48M303.4M333.21M326.37M400.07M
Other Income / Expenses(250.67M)(198.01M)(269.04M)(380.78M)(418.14M)
Income Before Tax135.45M(560.74M)(107.06M)(1.77B)(373.08M)
Pre-Tax Margin12.1%-51.9%-11.1%-190.3%-38.6%
Income Tax Expense33.37M12.17M(15.36M)(124.88M)(88.8M)
Net Income102.08M(572.91M)(91.7M)(1.65B)(284.28M)
Net Margin9.1%-53.1%-9.5%-176.9%-29.4%
EPS (Basic)6.40(35.87)(5.69)(101.92)(17.30)
EPS (Diluted)6.40(35.87)(5.69)(101.92)(17.30)
Weighted Avg Shares16.28M15.97M16.13M16.15M16.43M
Weighted Avg Shares (Diluted)16.29M15.97M16.13M16.15M16.43M

Claritev Corporation

NYSE:CTEV

Intrinsic Alpha fair value

Locked

Current Price

$22.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.